{"filing":{"accession_number":"0001193125-26-257423","cik":"0001637715","ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"okur-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/okur-20260603.htm"},"events":[{"id":3400,"run_id":2978,"accession_number":"0001193125-26-257423","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"OnKure held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on three proposals: election of Class II directors (Carruthers, Jansen, Mathers), ratification of KPMG LLP as independent auditor, and approval of the Amended and Restated 2024 Equity Incentive Plan. Vote results for all three proposals are disclosed with detailed tallies.","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-06-04","items":[{"id":4341,"accession_number":"0001193125-26-257423","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from OnKure's June 3, 2026 Annual Meeting of Stockholders, covering three proposals: election of Class II directors (Carruthers, Jansen, Mathers), ratification of KPMG LLP as independent auditor, and approval of the Amended and Restated 2024 Equity Incentive Plan. The filing presents vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:54.621608+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":3401,"run_id":2978,"accession_number":"0001193125-26-257423","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Stockholders approved an amendment and restatement of the 2024 Equity Incentive Plan at the June 3, 2026 Annual Meeting, which includes a one-time 8% increase in reserved shares (3,231,638 shares), removal of annual evergreen limits, and restrictions on incentive stock options. This material compensatory arrangement directly impacts the equity grant structure for officers and directors.","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-06-04","items":[{"id":4340,"accession_number":"0001193125-26-257423","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on amendment and restatement of the 2024 Equity Incentive Plan, including a one-time 8% increase in reserved shares (3,231,638 shares), removal of annual evergreen limits, and restrictions on incentive stock options. This is a material compensatory arrangement affecting equity grants to officers and directors, approved by stockholders at the Annual Meeting on June 3, 2026, and directly impacts executive compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:54.621608+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4340,"accession_number":"0001193125-26-257423","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on amendment and restatement of the 2024 Equity Incentive Plan, including a one-time 8% increase in reserved shares (3,231,638 shares), removal of annual evergreen limits, and restrictions on incentive stock options. This is a material compensatory arrangement affecting equity grants to officers and directors, approved by stockholders at the Annual Meeting on June 3, 2026, and directly impacts executive compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:54.621608+00:00","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-06-04"},{"id":4341,"accession_number":"0001193125-26-257423","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from OnKure's June 3, 2026 Annual Meeting of Stockholders, covering three proposals: election of Class II directors (Carruthers, Jansen, Mathers), ratification of KPMG LLP as independent auditor, and approval of the Amended and Restated 2024 Equity Incentive Plan. The filing presents vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal, which is the standard format for Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:54.621608+00:00","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-06-04"}]}